Abstract: Slide Presentations |

Chemotherapy With Sparfloxacin, Kanamycin, Pyrazinamide, Ethionamide and Ethambutol in Indian Patients having Multi-drug Resistant Tuberculosis FREE TO VIEW

Sudhir K. Agarwal, MD
Author and Funding Information

Institute of Medical Sciences, BHU, Varanasi, India


Chest. 2003;124(4_MeetingAbstracts):107S. doi:10.1378/chest.124.4_MeetingAbstracts.107S-a
Text Size: A A A
Published online


PURPOSE:  To determine the safety and efficacy of sparfloxacin along with kanamycin, pyrazinamide, ethionamide and ethambutol in Indian patients having multi-drug resistant tuberculosis. Efficacy was assessed by sputum smear and culture negativity at the end of 20 weeks.

METHODS:  124 patients (aged 18 years to 50 years) of multi-drug resistant tuberculosis (MDR-TB) were given 400 mg of sparfloxacin along with kanamycin, pyrazinamide, ethionamide and ethambutol under direct supervision. All patients were HIV negative, smear-positive, non-pregnant and had been receiving anti-tuberculosis drugs for an average of 72 weeks (31 to 125 weeks). All patients had isolates resistant to both isoniazid and rifampicin. Kanamycin was given in the dose of 25 mg/kg body weight on alternate days for 16 weeks. Pyrazinamide was stopped after 12 weeks of therapy. Sputum examination for acid-fast bacilli was done every 4 weeks up to 20 weeks to know smear and culture negativity.

RESULTS:  Three patients were withdrawn from the trial because of kanamycin induced ototoxicity. Sparfloxacin was stopped in three patients because of severe phototoxicity and in 2 patients because of prolongation of electrographic QTc interval. One hundred and sixteen out of 124 patients received sparfloxacin for 20 weeks. After 20 weeks smear conversion was in 99 (85%) and culture conversion in 86 (74%) patients.

CONCLUSION:  Treatment with sparfloxacin along with kanamycin, ethionamide, pyrazinamide and ethambutol in patients with MDR-TB has favourable response with acceptable phototoxicity.

CLINICAL IMPLICATIONS:  Chemotherapy with sparfloxacin, kanamycin, pyrazinamide, ethionamide and ethambutol seems to be promising for Indian patients MDR-TB.

DISCLOSURE:  S.K. Agarwal, None.

Tuesday, October 28, 2003

12:30 PM - 2:00 PM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543